RxDoctor Payments Data

Stacy Ingram-Hanson, NP

Nurse Practitioner · Colonial Heights, VANPI 1699748905

Payments from drug & device makers

$254in general payments, 2019–2025

Across 6 payments — averaging $42.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$110
  • Astellas Pharma US Inc$85
  • AstraZeneca$24
  • Bayer$20
  • Amgen$13
  • Genentech USA, Inc.$2

What the payments were for

  • Food & beverage$15059%
  • Education$10541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$254 in reported general payments places this provider in the 65th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$123,225
Medicare patients
385
Services billed
1,831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$77,582
OzempicSemaglutide61$65,849
JanuviaSitagliptin Phosphate70$64,882
TrulicityDulaglutide56$64,348
JardianceEmpagliflozin61$49,440
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$23,575
XareltoRivaroxaban18$13,506
FarxigaDapagliflozin Propanediol16$13,399
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$11,294
JanumetSitagliptin Phos/Metformin Hcl17$10,139
Diclofenac Sodium119$6,399
Breo ElliptaFluticasone/Vilanterol16$6,362
Colesevelam Hcl20$5,778
Dexlansoprazole DrDexlansoprazole25$5,524
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$5,085

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$110$65,84961 claims
AstraZenecaFarxiga, Symbicort$24$17,90029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Colonial Heights

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →